Phase 2 Piclidenoson trial planned in Lowe syndrome
Can-Fite launched its first clinical program testing Piclidenoson in Lowe syndrome, a rare inherited disorder with no approved disease-modifying treatments.
Results have not been presented; the Phase 2 trial is planned to run for six months.
The open-label, single-center study will treat 5 adults twice daily to assess whether kidney function shows meaningful improvement.
Positive findings are intended to support regulatory discussions and could shape a potential registration path for the drug in this indication.
CANF•
